Baird Upgrades Quest Diagnostics to Outperform, Raises Price Target to $182
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Eric Coldwell has upgraded Quest Diagnostics (NYSE:DGX) from Neutral to Outperform and increased the price target from $157 to $182.
October 23, 2024 | 11:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst Eric Coldwell has upgraded Quest Diagnostics from Neutral to Outperform, raising the price target from $157 to $182. This upgrade suggests a positive outlook for the company's stock performance.
The upgrade from Neutral to Outperform by a reputable analyst and the increase in price target indicate a positive sentiment towards Quest Diagnostics' future performance. This is likely to attract investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100